Alvotech (ALVO) and Advanz Pharma said Monday that the European Medicines Agency accepted the marketing authorization application for AVT05 to treat several chronic inflammatory diseases.
AVT05 is a biosimilar of Simponi and Simponi Aria, or golimumab, which are marketed by Johnson & Johnson's (JNJ) Janssen Biotech unit.
The approvals process is projected to close in Q4 2025, according to the companies.
Price: 13.00, Change: -0.02, Percent Change: -0.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments